Hot Features
Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Inovio Receives Advanced Therapy Medicinal Product Certificate from European Medicines Agency for Quality and Non-Clinical Data for Lead Candidate INO-3107 PR Newswire PLYMOUTH MEETING, Pa., July...
INOVIO to Report Second Quarter 2024 Financial Results on August 8, 2024 PR Newswire PLYMOUTH MEETING, Pa., July 25, 2024 PLYMOUTH MEETING, Pa., July 25, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO...
INO-3107 Awarded the Innovation Passport Designation Under U.K. Government's Innovative Licensing and Access Pathway PR Newswire PLYMOUTH MEETING, Pa., July 11, 2024 Award recognizes the...
INOVIO Announces Appointment of Steven Egge as Chief Commercial Officer PR Newswire PLYMOUTH MEETING, Pa., July 2, 2024 Mr. Egge brings over 25 years of biopharmaceutical experience building...
INOVIO Reports Inducement Grant Under Inducement Plan PR Newswire PLYMOUTH MEETING, Pa., July 1, 2024 PLYMOUTH MEETING, Pa., July 1, 2024 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology...
INOVIO Added to Russell 2000® Index Effective July 1, 2024 PR Newswire PLYMOUTH MEETING, Pa., July 1, 2024 PLYMOUTH MEETING, Pa., July 1, 2024 /PRNewswire/ -- INOVIO (NASDAQ: INO), a...
INOVIO to Participate in Virtual Fireside Chat Hosted by Stephens Inc. PR Newswire PLYMOUTH MEETING, Pa., June 4, 2024 PLYMOUTH MEETING, Pa., June 4, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a...
INOVIO Reports Inducement Grants Under Inducement Plan PR Newswire PLYMOUTH MEETING, Pa., May 31, 2024 PLYMOUTH MEETING, Pa., May 31, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
